Skip to main content

Advertisement

Table 1 Outcome of the evaluated parameters during twelve months of anticoagulant treatment with warfarin and rivaroxaban in the patients with paroxysmal nocturnal haemoglobinuria

From: Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events

  W R W R W R
  Pt 1: Female, 45 yrs. Pt 2: Female, 66 yrs. Pt 3: Female, 45 yrs.
Thrombosis of superior sagittal sinus Thrombosis of portal vein Deep vein thrombosis
Haemoglobin (gr/dL) 7. 7± 0.4 8.4 ± 0.6 0.006 12.5 ± 0.6 13.1 ± 0.2 n. s. 7.9 ± 0.5 7.8 ± 0.6 n. s.
Haematocrit (%) 22.9 ± 2 25.4 ± 1.4 0.003 38.5 ± 1.4 39.4 ± 0.7 n. s. 27.8 ± 1.6 28.6 ± 2.8 n. s.
Platelets (×  103/μL) 81.9 ± 9.4 73.8 ± 10.3 n. s. 118.1 ± 24.2 112.3 ± 6.7 n. s. 357.2 ± 27.2 347.3 ± 28.8 n. s.
Lactate deydrogenase (IU/L) 326.7 ± 15.0 311.7 ± 11.4 n. s. 249.1 ± 44.4 257.3 ± 40.1 n. s. 331.6 ± 207.3 312.8 ± 177.3 n. s.
Bleeding Days 6.0 ± 0.8 3.6 ± 0.7 0.001       
Low Molecular Weight Heparin (Days of bridging-therapy) 8.2 ± 0.7 1.7 ± 1.1 < 0.001       
Red Blood Cell Units transfused 11 4 0.03 0 0   6 6  
Diapers (number) 14.9 ± 0.6 10 ± 0.8 < 0.001       
Hospital admissions (Days per month) 4.2 ± 0.7 2.7 ± 0.8 < 0.001 3.7 ± 0.6 2.8 ± 0.6 0.001 4.0 ± 0.7 2.6 ± 0.8 0.001
  Pt 4: Male, 27 yrs. Pt 5: Female, 54 yrs. All patients
Thrombosis of portal vein Thrombosis of caval vein
Haemoglobin (gr/dL) 13.3 ± 0.6 13.6 ± 0.9 n. s. 10.9 ± 0.3 10.5 ± 0.2 n. s. 9.9 ± 2.5 9.8 ± 2.4 n. s.
Haematocrit (%) 39.9 ± 1.9 39.3 ± 3.3 n. s. 33.7 ± 1.4 31.0 ± 1.0 n. s. 31.4 ± 7.0 30.5 ± 5.7 n. s.
Platelets (× 103/μL) 94.3 ± 9.9 94.4 ± 11.5 n. s. 186.7 ± 23.9 192.5 ± 13.9 n. s. 186.3 ± 120.5 191.9 ± 123.0 n. s.
Lactate deydrogenase (IU/L) 228 ± 28.1 200.7 ± 21.4 n. s. 310.3 ± 57.4 272.0 ± 6.0 n. s. 285.9 ± 107.3 274.4 ±100.0 n. s.
Bleeding Days          
Low Molecular Weight Heparin (Days of bridging-therapy)          
Red Blood Cell Units transfused 0 0   0 0   17 10 n. s.
Diapers (number)          
Hospital admissions (Days per month) 3.5 ± 0.5 2.2 ± 0.4 0.001 3.1 ± 0.5 2.2 ± 0.6 < 0.001 3.7 ± 0.7 2.5 ± 0.7 < 0.001
  1. Reported data are the mean values and standard deviations of the evaluated parameters performed every month for twelve months during the treatment with warfarin (W) and rivaroxaban (R)
  2. Statistical analysis was performed using Student’s t-test. Significant level was set to p < 0.05. n. s. = not significant